Comparative Pharmacology
Head-to-head clinical analysis: LOPRESSOR HCT versus VISKAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOPRESSOR HCT versus VISKAZIDE.
LOPRESSOR HCT vs VISKAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOPRESSOR HCT is a combination of metoprolol tartrate (a beta-1 selective adrenergic receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Metoprolol reduces heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing plasma volume.
Viskazide is a combination of pindolol (a non-cardioselective beta-blocker with intrinsic sympathomimetic activity) and hydrochlorothiazide (a thiazide diuretic). Pindolol competitively blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, decreasing sodium and water reabsorption, leading to reduced plasma volume and blood pressure.
1-2 tablets (each containing metoprolol tartrate 50 mg and hydrochlorothiazide 25 mg) orally once daily, maximum 4 tablets daily.
Oral: 1 tablet (pindolol 10 mg / hydrochlorothiazide 25 mg) once daily; may increase to 2 tablets once daily if needed.
None Documented
None Documented
Metoprolol: 3-7 hours (terminal half-life); extensive metabolizers (CYP2D6) ~3-4 h, poor metabolizers ~7-8 h. Hydrochlorothiazide: 6-15 hours (terminal half-life).
Terminal elimination half-life is 10-12 hours for the hydrochlorothiazide component and 4-6 hours for pindolol; clinical context: steady-state achieved in 2-3 days for pindolol and 3-5 days for hydrochlorothiazide.
Metoprolol: <5% unchanged in urine; rest metabolized in liver (CYP2D6) and excreted renally as metabolites. Hydrochlorothiazide: >95% excreted unchanged in urine within 24 hours via tubular secretion.
Renal elimination (approximately 70% unchanged), with the remainder as inactive metabolites; biliary/fecal excretion is minor (<10%).
Category C
Category C
Beta-Blocker/Thiazide Diuretic Combination
Beta Blocker/Thiazide Diuretic Combination